News

By Felipe de Araújo Monteiro

Increase in Patients Using Medicinal Cannabis and Its Consequences

The number of Brazilians using medicinal cannabis-based medications increased by approximately 165% in one year, representing a jump from 188,000 to 430,000 patients who used medicinal cannabis this year. As a result, companies assisting in the importation of these medications to Brazil reported a 1,241% increase in their requests to the National Health Surveillance Agency (Anvisa) during this period.

In this sense, it can be said that there is a growing demand for these medications and, consequently, an increase in the expenses of the Ministry of Health in the delivery of cannabis-based medications, which are provided based on a judicial order or under the justification of guaranteeing access to treatment and maintenance of health. It is important to clarify that, due to the increase in requests for medications with CBD (cannabidiol), in 2021, the Ministry of Health spent around R$ 160,690.00 with the provision of these medicines, while the following year, the expenditure was R$ 1,671,701.00 and, only in the first quarter of 2023, the Ministry of Health spent around R$ 767,906.00 with the provision of the medications.

The filing of lawsuits seeking the provision of these medications is becoming increasingly common, given that the process to acquire cannabis-based medications is time-consuming and often costly for the patient. Currently, these medications can be obtained in three ways:

(i) through importation, with a medical prescription and authorization from Anvisa.

(ii) purchase at pharmacies – with 34 authorized products – upon presentation of a medical prescription.

(iii) through a safe-conduct for domestic cannabis cultivation granted by the judiciary.

The growth in patients using medicinal cannabis can be explained by advances in research and an increase in indications for the use of these medications. Currently, approximately 12,000 doctors have prescribed cannabis-based products at least once, according to the consultancy Kaya Mind.

Therefore, given the exponential growth in patients using cannabis-based medications, it is important to have public policies for the provision of these medications. These policies should ensure greater state control over the purchase, inventory, supply, and monitoring of patients.

For more content related to the regulation of medicinal cannabis, do not hesitate to contact us by email: regulatorio@kasznarleonardos.com.

Back

Last by Felipe de Araújo Monteiro

April 22, 2024

New Rules for Payment Transactions by Fixed-Odds Betting Operators in Brazil

In a further step towards regulating the new Betting Law (Law No. 14,790/2023), Normative Ordinance SPA/MF No. 615, of April 16, 2024, New Rules for Payment Transactions by Fixed-Odds Betting Operators in Brazil

Ler notícia

April 17, 2024

Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines

Anvisa recently launched a public notice with the aim of selecting Startups involved in the research and development of medicines, in order Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines

Ler notícia

April 11, 2024

Ministry of Finance Defines Regulatory Agenda for the Betting Market

In another step towards the realization and consolidation of the regulations provided for by the New Betting Law (Law 14.790/2023), the Ministry Ministry of Finance Defines Regulatory Agenda for the Betting Market

Ler notícia
plugins premium WordPress